NCT02340780 - Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 27, 2015

Primary Completion Date

November 21, 2018

Study Completion Date

April 28, 2020

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

Buparlisib

Trial Locations (6)

Tom Baker Cancer Centre, Calgary

Cross Cancer Institute, Edmonton

CancerCare Manitoba, Winnipeg

QEII Health Sciences Centre, Halifax

University Health Network, Toronto

The Jewish General Hospital, Montreal